Evidence map›Paper›PMID 42699572›Full record

ArticleiScience2026

MAPK-driven MYC/p21 axis controls senescence bypass and BCL-XL dependence in vincristine-resistant rhabdomyosarcoma.

Yadong Wang, Andrea D Largent, Dorothy Lee, Paulomi Modi, Long Wang, Anshu Bandhlish, Myron Ignatius, Eleanor Y Chen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yadong WangDepartment of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA.
Andrea D LargentDepartment of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA.
Dorothy LeeDepartment of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA.
Paulomi ModiGreehey Children's Cancer Research Institute, Department of Molecular Medicine, University of Texas Health Sciences Center, San Antonio, TX, USA.
Long WangGreehey Children's Cancer Research Institute, Department of Molecular Medicine, University of Texas Health Sciences Center, San Antonio, TX, USA.
Anshu BandhlishDepartment of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA.
Myron IgnatiusGreehey Children's Cancer Research Institute, Department of Molecular Medicine, University of Texas Health Sciences Center, San Antonio, TX, USA.
Eleanor Y ChenDepartment of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Therapy resistance remains the primary cause of treatment failure in rhabdomyosarcoma (RMS), the most common pediatric soft tissue sarcoma, yet underlying mechanisms are poorly understood. Using vincristine-resistant fusion-negative RMS models, RNA sequencing, genetic perturbations, and a syngeneic zebrafish tumor model, we demonstrate that resistance is driven by enhanced MAPK signaling, validated in post-chemotherapy patient specimens. MEK inhibition induced senescence through an MYC-p21 axis; MYC represses CDKN1A transcription, and its overexpression bypasses senescence. Resistant cells exhibited BCL-XL dependence, and combined MEK/BCL-XL inhibition eradicated resistant tumors

Indexed as

BCL-XLMAPKMEKMYCresistancerhabdomyosarcomasenescencetrametinibvincristine

Identifiers

PMID42699572
PMCPMC13543793

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.